Evommune Inc. (EVMN) is approaching pivotal catalysts, with two clinical trial data readouts expected in the first half of 2026.
The company is advancing EVO301, a Phase 2a study in atopic dermatitis, and EVO756, a dose-ranging Phase 2b trial in chronic spontaneous urticaria, both targeting chronic inflammation.
Atopic dermatitis affects millions worldwide, and current therapies often fail to provide durable relief, positioning EVO301 as a potential novel option in this underserved space.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com